Actively Recruiting
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
Led by AbbVie · Updated on 2026-03-27
2000
Participants Needed
4
Research Sites
29 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, relapsing, and often disabling condition characterized by inflammation of the gastrointestinal tract. A treat-to-target strategy (T2T) is recommended by international guidelines to optimize long-term outcomes in IBD. The purpose of this study is to describe the real-life implementation of T2T in IBD worldwide and the association between using a T2T strategy and disease outcomes. This is a multi-country, observational, retrospective (non-interventional) study with a cross-sectional component based upon a sample of adult participants with IBD. All objectives will be assessed for IBD and then for CD/UC separately. Primary and secondary objectives will be assessed for the overall population over the 24 months study period. As this is an observational study, enrolled participants will be managed and followed up according to the standard practice. Retrospective chart review over the 24-months from date of inclusion will allow us to collect the variables of interest by using an e-CRF. There will be no additional burden for participants in this trial. Study visits will not be required as this is a retrospective chart review.
CONDITIONS
Official Title
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult male and female participants (>= 18 years old) at the inclusion date who present within the usual course of care
- Participants able to provide voluntary informed consent prior to any study data collection
- Participant diagnosed with Crohn's Disease (CD) or Ulcerative Colitis (UC) for at least 24 months at the inclusion date
- With >= 24 months of available medical records from the inclusion date
You will not qualify if you...
- Participants who had received treatment with any investigational drug/device/intervention over the past 24 months prior to the enrolment
- Participants under legal protection
- History of proctocolectomy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Chongqing General Hospital /ID# 282777
Chongqing, Chongqing Municipality, China, 400013
Actively Recruiting
2
Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau /ID# 282775
Nîmes, Gard, France, 30029
Not Yet Recruiting
3
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois /ID# 280265
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France, 54511
Not Yet Recruiting
4
CHU Amiens-Picardie Site Sud /ID# 280263
Amiens, Somme, France, 80054
Not Yet Recruiting
Research Team
C
Colla Cunneen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here